Medical Writing & Publication Planning: An Industry Guide

Published November 15, 2025 35 min read


Medical Writing & Publication Planning: An Industry Guide

Medical Writing & Publication Planning: An Industry Guide

Executive Summary

The scientific publication planning and medical writing sector has grown into a multibillion-dollar global industry. Recent market analyses estimate the global medical writing market at roughly **$3.8–5.1 billion** (depending on scope) with forecasts to exceed **$6–10+ billion by 2030–2032** (Source: www.grandviewresearch.com) (Source: www.mordorintelligence.com). This expansion is driven by rising R&D investments in biotechnology and pharmaceuticals, globalization of trials, and the increasing complexity of regulatory requirements. About **35%** of the market (2022) was in North America (Source: www.grandviewresearch.com), though Asia-Pacific is projected to be the fastest-growing region. The sector spans a wide range of document types – from regulatory submissions (protocols, clinical study reports) to publications (journal articles, conference abstracts) and educational materials – all requiring scientific and technical writing expertise. The top service providers include major contract research organizations (CROs) and specialized medical communications agencies, such as **IQVIA, Parexel, Syneos Health (now privately held), Avalere Health (formerly Fishawack), Fortrea (spun off from LabCorp), Trilogy Writing & Consulting**, among others (Source: www.verifiedmarketresearch.com) (Source: www.verifiedmarketresearch.com). These firms boast global footprints and integrate publication planning into broader development and commercialization strategies.

Professional medical writers contribute to many published studies. In one cross-sectional sample of 270 oncology trials published in six high-impact medical and oncology journals from May 2021 to May 2022, 141 (52.2%) identified medical-writer support; this disclosure-based measure cannot establish all actual use of writers (Source: pmc.ncbi.nlm.nih.gov). Good Publication Practice (GPP) guidelines and codes of ethics have been instituted to ensure transparency, requiring that writing assistance be disclosed and aligned with ethical standards (Source: pubmed.ncbi.nlm.nih.gov) (Source: pmc.ncbi.nlm.nih.gov). The latest iteration, **GPP 2022**, expanded guidance to cover all types of biomedical research, social media, and patient involvement in publication planning (Source: ismpp.org). Going forward, emerging technologies (e.g. AI-assisted writing) and regulations (e.g. requirements for lay summaries of trial results, FDA and EMA AI guidance) are reshaping the field. This report provides a comprehensive review of the publication planning and medical writing industry: its history, market dynamics, services offered, leading providers, challenges (e.g. ghostwriting controversies, regulatory compliance), and future trends.

Introduction

Scientific publication planning and medical writing services are specialized professional functions within the life sciences sector. They ensure that clinical and scientific data (often generated by pharmaceutical/biotech companies or academic researchers) are effectively communicated to target audiences — including regulatory authorities, healthcare professionals, and patients. **Publication planning** typically refers to the process of strategizing *which* research findings to publish, in *which* journals or conferences, on *what* timeline, and under *which* authorship. **Medical writing services** encompass the actual preparation of documents: ranging from regulatory dossiers (e.g. *Clinical Study Reports*, *New Drug Applications*) to scientific manuscripts and educational materials. As one review notes, publication planning "shapes pharmaceutical companies' data and eventually turns it into medical journal articles, especially those reporting on clinical trials" (Source: journals.library.ualberta.ca).

The importance of these services has grown dramatically. Increased R&D spending by industry and academia, proliferating clinical trials, and the need for compliant, timely dissemination of results all drive demand. For example, by 2018 roughly **80% of internet users** in the United States reported searching for health-related information online (Source: www.grandviewresearch.com), reflecting a broader trend of stakeholders (patients, clinicians) seeking scientific knowledge. In this information age, accurate and accessible presentation of medical data is critical. Moreover, authorities and publishers now expect rigorous standards: the ICMJE publishes its own Recommendations on authorship, disclosure, and related editorial responsibilities, while **GPP 2022** is guidance for company-sponsored biomedical research published in *Annals of Internal Medicine* and supported by ISMPP. Together, these resources emphasize ethics, transparency, and appropriate authorship and contributor attribution (Source: pubmed.ncbi.nlm.nih.gov) (Source: journals.library.ualberta.ca).

Historically, the role of professional medical writers and planners became prominent in the late 20th century. (For example, the American Medical Writers Association traces its origins to 1949, and ISMPP was founded in 2002.) Controversies over undisclosed "ghostwriting" in drug company–funded publications during the 1990s and 2000s spurred much of the current regulatory landscape (Source: www.theguardian.com) (Source: journals.library.ualberta.ca). Consequently, pharmaceutical companies now often outsource writing tasks to specialized agencies or employ in-house writers who are trained to comply with evolving guidelines. The result is a sizeable ecosystem of organizations dedicated to medical writing and publication planning.

This report examines the **current state** of that ecosystem and its future directions. We review market data and growth drivers, the spectrum of services offered, types of documents produced, and key players in the global marketplace. Market-size and segmentation figures are drawn from commercial industry analyses and are presented as third-party estimates whose definitions and methodologies may differ (Source: www.grandviewresearch.com) (Source: www.mordorintelligence.com). We synthesize case studies and surveys, including a sample in which 141 of 270 published oncology trials identified medical-writer support (Source: pmc.ncbi.nlm.nih.gov), to illustrate real-world practices. Multiple perspectives are considered: from pharmaceutical sponsors' needs to best-practice guidelines from professional bodies. Technical advancements (digital platforms, AI tools) and regulatory trends (open-access mandates, patient-centered communication) are discussed in the context of implications for the field. The analysis draws on industry analyses, surveys, and guidance from professional and regulatory bodies.

Market Size and Growth

The global market for medical writing and communications has been expanding briskly. Two recent market research analyses estimate the sector's value in the **low-single-digit billions of USD** with double-digit annual growth. Grand View Research (2023) reports that the global medical writing market was **≈$3.8 billion in 2022** (USD) and projects it to reach **$8.4 billion by 2030**, reflecting a compound annual growth rate (CAGR) of **~10.46% (2023–2030)** (Source: www.grandviewresearch.com). Similarly, Mordor Intelligence projects that the market in 2025 is near **$3.94 billion** and will grow at ~**10.12% CAGR** to about **$6.38 billion by 2030** (Source: www.mordorintelligence.com). In practical terms, this growth is driven by several factors: rising global R&D spending, increasing clinical trial activity (especially in emerging markets), and greater outsourcing of writing tasks by companies seeking specialized expertise (Source: www.grandviewresearch.com) (Source: www.mordorintelligence.com).

SOURCE / REPORT	ESTIMATED MARKET SIZE (USD)	CAGR	FORECAST
Grand View Research (2023) (Source: www.grandviewresearch.com)	$3.8 billion (2022)	~10.5% (2023–2030)	$8.4 billion (2030)
Mordor Intelligence (2025) (Source: www.mordorintelligence.com)	$3.94 billion (2025)	~10.12% (2025–2030)	$6.38 billion (2030)
Coherent Market Insights (2025) (Source: globenewswire.com)	$5.10 billion (2025)	~10.5% (2025–2032)	$10.26 billion (2032)

Recent market reports note that **North America** is the largest regional market (≈35–36% share in 2022) (Source: www.grandviewresearch.com), reflecting the concentration of major pharma and biotech companies. **Europe** is also substantial, and **Asia-Pacific** is expected to register the fastest growth rate during this decade (Source: www.grandviewresearch.com). The Asia-Pacific boom correlates with increasing R&D operations in countries such as China and India, and the globalization of clinical research.

The market breaks down by service type as well. **Clinical/regulatory writing** (documents supporting drug approval) typically dominates the revenue share (e.g. 38.1% share in 2022 (Source: www.grandviewresearch.com), followed by publications and medical communication projects. Notably, one report predicts that **medical education/marketing writing** (informational materials for healthcare providers and patients) will see the fastest growth (Source: www.grandviewresearch.com). This aligns with broader trends in patient engagement and digital health.

Several indicators confirm the sector's expansion. For example, a 2025 survey by Bernisson et al. identified at least **1,148 companies worldwide** offering medical writing services (Source: academic.oup.com). Similarly, a 2014 BMJ survey of medical publication professionals found that **over 90% of companies** (pharma or agencies) maintained formal publication policies and nearly all (96–99%) required that medical writing support be acknowledged in manuscripts (Source: pmc.ncbi.nlm.nih.gov). These facts suggest a highly structured and widespread industry presence across global institutions.

Drivers of Growth

Several key drivers underpin the growth of publication planning and medical writing services:

- **R&D and Clinical Trials**: As global R&D budgets rise, the volume of trial data explodes. Pharmaceutical and biotech firms generate complex datasets requiring skilled writers to interpret. The launch of new drug therapies – especially in specialty areas – depends on timely publication of positive (and sometimes negative) findings in the literature.
- **Regulatory Complexity**: Meeting the requirements of health authorities (FDA, EMA, etc.) requires voluminous documentation. Guidelines such as ICH's Common Technical Document format necessitate professional writing. New regulations (e.g. EU Clinical Trials Regulation mandating lay summaries) have also expanded the scope of writing tasks.
- **Outsourcing Trends**: Many companies lack enough in-house writing staff. Thus, they outsource to specialized agencies or independent medical writers. Outsourcing allows flexibility and tapping into niche expertise (e.g. in rare disease or novel therapeutic areas).
- **Transparency and Ethics**: After high-profile controversies around ghostwriting, companies now emphasize ethical publication practices. The adoption of Good Publication Practice guidelines — from **GPP3** (2015) to the current **GPP 2022** — ensures companies invest in professional writing to adhere to best practices (Source: pubmed.ncbi.nlm.nih.gov). GPP 2022 expanded its scope beyond clinical trials to all biomedical research and added guidance on social media and patient involvement (Source: ismpp.org). These guidelines also implicitly elevate the value of well-trained publication planners and writers who know to disclose conflicts and attribution correctly.
- **Digital Communication**: The rise of digital channels (online journals, webinars, social media) has expanded the remit of medical communication. Agencies now often handle content development for digital platforms, podcasts, and web-based education, supplementing traditional writing tasks.

The industry's upward trajectory is also reflected in acquisitions and consolidation. Leading CROs and marketing firms frequently integrate medical communication boutiques to offer **"end-to-end"** solutions. For example, Fishawack Health acquired 19 agencies over two decades before rebranding as **Avalere Health** in 2023, positioning itself as a global commercialization partner spanning medical, marketing, and policy consulting (Source: fiercepharma.com). **Syneos Health** was taken private in September 2023 by a consortium of Elliott Investment Management, Patient Square Capital, and Veritas Capital in a **$7.1 billion** deal (Source: syneoshealth.com). Similarly, large CROs like Parexel continue to expand their medical communications offerings to provide publication planning in conjunction with clinical trial services (Source: www.verifiedmarketresearch.com).

Market Segmentation

The medical writing market can be segmented by **type of writing** and **end-use**. Key segments include:

- **Regulatory Writing**: Documents for regulatory submissions (protocols, informed consent forms, investigator brochures, regulatory dossiers). This segment held the largest share in 2022 (Source: www.grandviewresearch.com), due to growing pre- and post-approval documentation.
- **Clinical Study Reports (CSRs)** and **Submissions**: Often grouped with regulatory, these formal comprehensive reports account for significant workload and cost.
- **Manuscripts & Publications**: Full-length journal articles, review articles, editorials, and book chapters. Growth in academic and sponsored research drives this segment.
- **Abstracts & Conference Materials**: Including posters, oral presentation slides for scientific congresses.
- **Medical/Scientific Communications**: Broader category covering medical education materials, promotional medical writing (non-advertising), healthcare professional newsletters, patient education content. Medico-marketing writing (brochures, websites, commercials) also falls here; one report notes this category has the fastest projected CAGR (Source: www.grandviewresearch.com).
- **Other Specialized Writing**: Including pharmacoeconomic reports, health technology assessments (HTAs), payer dossiers, training modules, etc.

End-user sectors include **pharmaceutical/biotech companies**, **contract research organizations (CROs)** (which act as service providers), **medical device firms**, **hospitals and academic institutions**, and to a lesser extent **government and non-profits**. According to a global survey, about 62% of publication professionals worked for pharma/biotech companies, 51% for medical communications agencies, and 3% in CROs (Source: pmc.ncbi.nlm.nih.gov), illustrating that the industry is served by both internal company teams and external agencies.

Publication Planning: Strategy and Process

Publication planning is a strategic, proactive process undertaken to maximize the scientific impact and regulatory compliance of a product's data dissemination. It involves **mapping out a publication calendar** for a therapy or program, often spanning from Phase I through post-marketing. A robust publication plan aligns with clinical development timelines, anticipated regulatory milestones, and important medical congresses or journal deadlines.

Objectives and Scope

The core purpose of publication planning is to "create and communicate scientific information to support the marketing of products" (Source: journals.library.ualberta.ca). In practice, this means:

- **Prioritizing Key Data**: Determining which clinical trial results warrant publication (positive or negative) and in what format.
- **Identifying Target Journals/Conferences**: Selecting high-impact but appropriate venues. (For example, oncology data might be targeted to *Journal of Clinical Oncology* or *ASH Annual Meeting*.)
- **Coordinating Authors and Collaborators**: Engaging Key Opinion Leaders (KOLs), investigators, and internal experts to serve as authors, while managing contributions and agreements.
- **Ensuring Timeliness**: Drafting documents in sync with regulatory filings or product launches, so that data is publicly available when needed.
- **Compliance and Integrity**: Verifying adherence to ethical standards, e.g. ICMJE authorship criteria and GPP3 principles, and ensuring proper disclosure (funding, writing assistance) in all publications.

A formal publication plan often contains a timeline (sometimes as an Excel schedule) with rows for each planned deliverable (e.g. abstract submission Q3 2024, manuscript Q1 2025) and columns for status, authors, conferences, etc. Agencies offering publication planning services will handle much of this coordination on behalf of sponsors. For example, inSience Communications (Springer Nature) advertised positions involving "contributions to publication plans" (Source: academic.oup.com), underscoring how agencies embed publication strategy into their work.

Guidelines and Ethics

Publication planning today is tightly governed by ethical guidelines. The **GPP 2022** guideline (published in *Annals of Internal Medicine*, succeeding GPP3 from 2015) explicitly addresses publication planning, stating that professional planners should "maintain ethical and transparent publication practices" and comply with legal/regulatory requirements (Source: pubmed.ncbi.nlm.nih.gov). GPP 2022 expanded guidance to cover all types of biomedical research (not just clinical trials), social media communications, and patient involvement in the publication process. The guidelines emphasize that all contributions to publications must be appropriately acknowledged – meaning medical writers must be named or accredited – and that ghostwriting is unethical. Indeed, by 2013–14, over 95% of surveyed industry and agency professionals reported that their companies had codes of conduct governing ethical publication practices, and that training on publication ethics was nearly ubiquitous (Source: pmc.ncbi.nlm.nih.gov) (Source: pmc.ncbi.nlm.nih.gov).

In practice, pharmaceutical clients often require that any third-party writing support be disclosed (e.g. in the paper's acknowledgments or authorship). The prior characterization of publication planning as a marketing support activity (Source: journals.library.ualberta.ca) has prompted regulators and publishers to demand transparency. For instance, many journals now require disclosure of any medical writing assistance and funding sources. International guidelines (e.g. ICMJE Uniform Requirements, GPP3) also specify that authors must take responsibility for all content, which means a publication planner ensures that all listed authors have seen and approved the work.

Publication Planning Services

Agencies provide a spectrum of publication planning services, which can include:

- **Strategic Consulting**: Developing a publication plan aligned with product strategy. This may involve running "publications steering committees" or advisory boards.
- **Document Management**: Overseeing the writing, review, and approval process for manuscripts, slide decks, posters, etc.
- **Regulatory Support**: Ensuring consistency between publications and regulatory documents, avoiding conflicting data release.
- **Metrics**: Tracking publications output (e.g. journal impact factors, citations) to measure ROI on publication efforts.

These services emphasize project management and liaison roles as much as writing. Survey respondents noted that publication roles often involve "liaison between internal and external stakeholders, or clients and KOLs" (Source: academic.oup.com) – a vital skill set beyond pure writing.

Medical Writing Services: Activities and Expertise

Medical writing services broadly encompass the creation of scientific content across multiple contexts. The skill set typically requires advanced knowledge of life sciences (often writers have science or medical degrees) combined with writing and editing proficiency. Key categories of medical writing include:

- **Regulatory Writing**: Creation of documents for drug/device approval. This includes:
- **Study Protocols and Amendments**: Plans for clinical trial conduct.
- **Investigator Brochures**: Summaries of clinical and non-clinical data for investigators.
- **Clinical Study Reports (CSRs)**: Detailed narratives of trial methodology and results for submissions.
- **Regulatory Dossiers (e.g. CTD modules)**: Compilation of all data for marketing applications.

Regulatory writers must conform to strict templates (e.g. ICH E3 guideline for CSRs). Given the complexity, many companies engage writing services to draft or edit these documents.

- **Manuscript and Publication Writing**:
- **Original Research Articles**: Reporting clinical trial or basic research results.
- **Review Articles**: Syntheses of existing literature on a topic.
- **Case Reports, Commentaries, Letters**: Shorter scientific communications.
- **Abstracts and Posters**: Concise presentations of data for conferences.
- **KOL Communications**: Preparing slides and speaker notes for clinical presentations.
- **Clinical Communications and Presentations**:
- **Conference Materials**: Designing oral slides, poster content.
- **Symposia and Advisory Boards**: Whitepapers or background briefings.
- **MedEd Materials**: Educational content for healthcare professionals (e.g. slide sets, e-learning modules).
- **Medical Education for Patients and Public**:
- **Patient Education Sheets**: Summaries of disease understanding or trial results in plain language.
- **Lay Summaries**: Patient-friendly versions of study reports (e.g. as required by EU regulators).
- **Digital Content**: Website articles, blogs, social media content related to health topics.
- **Pharmacovigilance/Medical Affairs**:
- **Safety Reports**: Case narratives for adverse events.
- **Regulatory Labeling**: Drafting sections of drug labels (indications, dosing guidance).
- **Medical Inquiries Responses**: Standard replies to medical information queries.

Because of this diversity, medical writers often specialize (e.g. regulatory vs publications vs patient matter). Agencies staff writers with relevant expertise (physicians, pharmacists, life-science PhDs, etc.) to match topic needs.

Market Outlook and Training

The demand for qualified medical writers has increased across the world. One study of 270 oncology trials published in six high-impact medical and oncology journals found that 141 (52.2%) identified medical-writer support; because writers were identified from article disclosures, the result does not measure undisclosed support (Source: pmc.ncbi.nlm.nih.gov). Meanwhile, surveys of medical writers indicate that most have advanced degrees (the

BMJ survey found 62–79% had MD/PhD and 79% had ≥5 years experience (Source: pmc.ncbi.nlm.nih.gov). This reflects the specialized nature of the work.

Educational programs and certifications (e.g. the American Medical Writers Association certification, or the European Medical Writers Association courses) have grown to standardize skills. Many writers also have training in Good Clinical Practice (GCP) and regulatory requirements. The high educational level of most writers is consistent with the field's complex subject matter: a BMJ survey reported that **78% of responders had ≥5 years of experience and 56–62% held doctoral degrees** (Source: pmc.ncbi.nlm.nih.gov).

The industry's workforce constraints are a recognized challenge. Mordor Intelligence notes a "talent shortage" of skilled medical writers, which even drives wages up (Source: www.mordorintelligence.com). Some companies respond by adopting **AI-assisted tools** (e.g. for initial drafting, reference formatting, data extraction) to augment writer productivity, though experts caution that human oversight remains essential (Source: www.mordorintelligence.com).

Leading Service Providers

The global market is served by a mix of large CROs/consultancies and specialized communications agencies. Below we profile prominent players often cited as "top 10" providers of publication planning and medical writing services. (Company descriptions draw on industry profiles and press releases; citations indicate sources where applicable.)

COMPANY	COMPANY TYPE	KEY FOCUS / SERVICES	NOTES / CITATIONS
IQVIA (Durham, NC, 1982)	Integrated CRO and analytics	Broad clinical development + medical writing (protocols, dossiers, publications)	One of the world's largest CROs (Source: www.verifiedmarketresearch.com); merged with IMS Health in 2016.
Parexel (Newton, MA, 1982)	CRO and consultancy	Clinical trials, regulatory affairs, medical writing (protocols, CSRs, manuscripts)	Major CRO with global reach (Source: www.verifiedmarketresearch.com); winner of a 2018 Scrip Award.
Syneos Health (Morrisville, NC, 1968/1998)	CRO & commercialization (now private)	End-to-end clinical + commercial services, including medical communications	Formed by merger of INC Research and inVentiv (2018). **Taken private in Sept 2023** by Elliott/Patient Square/Veritas for $7.1B (Source: syneoshealth.com). Costa Panagos appointed CEO Oct 2024.
Inizio (formed 2022)	Medical communications & commercialization	Advisory, medical affairs, digital strategy, promotional review, patient solutions	Formed in 2022 from UDG Healthcare and Huntsworth. Operates Ashfield and other divisions globally, offering integrated healthcare communications and commercial services (Inizio's 2022 Sustainability Report.
Fortrea (Durham, NC; spun off 2023)	CRO (pharma R&D services)	Drug development services, clinical trials, medical writing of CSRs and regulatory reports	LabCorp **spun off its drug development business as Fortrea Holdings** in June 2023, now an independent publicly traded CRO. Continues the legacy of Covance's full-service drug development and medical writing capabilities.
Trilogy Writing & Consulting (Frankfurt, Germany, 2002)	Med comm agency (boutique)	Scientific publications, regulatory writing, publication planning	Boutique European agency founded by three medical writers (Source: www.verifiedmarketresearch.com); focuses on high-quality clinical writing (Source: www.verifiedmarketresearch.com).
Avalere Health (Basingstoke, UK / Washington DC; formerly Fishawack Health)	Med comm & policy consulting	Full-service healthcare communications, market access, policy consulting	**Rebranded from Fishawack Health to Avalere Health in 2023** after integrating 19 acquisitions. Revenue: $210M (2024). Owned by Bridgepoint PE. Positions as a "global commercialization partner" (Source: fiercepharma.com).
Springer Health+	Medical communications and education provider	Medical communications solutions, education initiatives, specialized training, and publication-related services	Springer Healthcare and inScience Communications rebranded together as Springer Health+ in May 2025. The historical global survey cited here identified inScience Communications by its former name (Springer Nature announcement (Source: academic.oup.com).
Indegene (Bangalore, India, 1998)	Pharma services company	Scientific/medical writing, digital	Large global agency (India-origin) offering end-to-end medical communications and digital services. **Completed IPO on Indian stock exchanges**

COMPANY	COMPANY TYPE	KEY FOCUS / SERVICES	NOTES / CITATIONS
		marketing, clinical operations support	**(NSE/BSE) in May 2024** at INR 452/share, massively oversubscribed at 70x. Market cap ~$1.25B as of early 2026.
Enago Life Sciences (Tokyo/NY, 2002)	Med/ed services (Editage)	Journal support (editing, translation, publication planning, indexing)	Known for publication support and educational services. Owned by Cactus Communications.
Others: E.g. **Apollogic** (Germany/USA), **SciencePartners** (Czech), **Phastar** (UK), **CCA (Choice)** (Spain), **CCI Europe**, etc. These boutique players specialize in various niches (e.g. oncology writing, digital solutions).			

Sources: Company profiles and announcements (e.g., IQVIA 2022 results (Source: www.iqvia.com), Syneos 2022 results (Source: www.syneoshealth.com), industry press (PMLiVE, PharmaVOICE), and academic analyses (Source: www.verifiedmarketresearch.com) (Source: www.verifiedmarketresearch.com) (Source: academic.oup.com).

This table highlights the diversity of providers. Interestingly, many large CROs (IQVIA, Parexel, Syneos, Fortrea) have built or acquired substantial medical writing teams to offer **integrated services**. Others (Trilogy, Avalere Health, Apollogic, etc.) are specialist agencies known for deep therapeutic expertise or high-touch service. In practice, sponsors often partner with such agencies for publication planning while their own staff (e.g. medical directors) provide oversight.

Data on Top Companies: To illustrate scale, IQVIA reported **$14.41 billion** in full-year 2022 revenue (Source: www.iqvia.com), and Syneos Health reported **$4.975 billion** in revenue for 2022 before going private. While not all of this revenue is from writing, it underscores the large size of these organizations. By contrast, smaller agencies like Trilogy or Avalere Health ($210M revenue in 2024) operate at a different scale. Certified rankings (e.g. Life Sciences Review *"Top 10 Medical Writing Companies"* lists) and directories (e.g. WE3 MedComms) consistently include these names among leaders in the field.

Market Dynamics and Data Analysis

Beyond overall market size, several data-driven insights illuminate how publication planning and medical writing are practiced:

- **Industry Survey – Publications Activity:** A cross-sectional study in *JAMA Network Open* (2023) examined oncology trials in top journals over one year. It found **52.2% of published trials (141 out of 270)** explicitly acknowledged medical writer support (Source: pmc.ncbi.nlm.nih.gov). Moreover, trials with writers were more likely to use surrogate endpoints (e.g. progression-free survival (Source: pmc.ncbi.nlm.nih.gov) and tended to report favourable outcomes (though this association did not hold after adjustment). The authors conclude that medical writers are integral to the dissemination of clinical trial results and that journals should scrutinize papers accordingly (Source: pmc.ncbi.nlm.nih.gov). This data point underscores the prevalence of medical writing in high-impact literature.

- **Global Publication Survey:** In a 2014 BMJ Open survey of publication professionals, respondents reported high compliance with best practices. Over **90%** said their organizations had formal publication guidelines, and **96–99%** required that medical writing assistance be acknowledged (Source: pmc.ncbi.nlm.nih.gov). Around 78% of respondents had a doctoral degree and most had >5 years' experience (Source: pmc.ncbi.nlm.nih.gov), reflecting a well-educated, experienced workforce. Roughly one-third of responders were industry employees, half worked for agencies, and a small fraction for CROs (Source: pmc.ncbi.nlm.nih.gov). This study implies a mature industry awareness of ethics and standard operating procedures.

- **Academic Literature:** Bernisson et al. (2025) conducted a broad bibliometric search to enumerate medical-writing companies by mining publication acknowledgements. They found **1,148 distinct entities** providing medical writing/services (Source: academic.oup.com). Even after removing NGOs/academics, this large number indicates the fragmentation and prevalence of minor niche firms. The study identified *inScience*

Communications (Springer Nature) as the largest contributor in its historical dataset, with 975 publications. Springer Healthcare and inScience Communications rebranded together as Springer Health+ in May 2025 (Springer Nature announcement (Source: academic.oup.com). The study also documented that job ads frequently describe medical writers as liaisons with KOLs and clients (Source: academic.oup.com), consistent with the survey findings on project coordination.

- **Market Drivers – Digital/Online:** Grand View Research (2023) notes **increasing internet use for health information** as a factor raising demand for medical content (Source: www.grandviewresearch.com). For example, they cite a 2018 report that *80% of US internet users search for health info* (and many trust social media posts) (Source: www.grandviewresearch.com). The implication is two-fold: (1) pharmaceutical companies increasingly engage in online medical education and must produce accurate digital content; (2) regulators and ethics boards are wary of misinformation, making rigorous writing more crucial.

These data underscore that publication planning/writing is no minor niche. It is embedded in the drug development lifecycle and heavily utilized by the industry, as evidenced by high acknowledgement rates and the global proliferation of service providers.

Challenges, Controversies, and Quality Assurance

Although the industry has professionalized, challenges remain. Key issues include:

- **Authorship and Ghostwriting:** The boundary between legitimate writing support and unethical ghostwriting can sometimes be blurred. Journals and watchdogs remain vigilant. For instance, a *Guardian* exposé (2009) revived discussion about ghostwriting when court documents revealed scheme by a UK doctor in favor of a drug company (Source: www.theguardian.com). In response, publishers now often require authors to declare that they “had full access to the data” and to identify all who wrote or funded the paper. Publication planning must contend with regulators’ ongoing push for transparency (Source: journals.library.ualberta.ca). To address this, publication professionals follow codes of ethics (e.g. ISMPP’s Code of Ethics) and increasingly must also navigate **AI disclosure requirements** — ISMPP published enhanced AI guidance in September 2025 covering education, implementation, and ethical use of AI in medical publications (Source: tandfonline.com). Continual training on "ethical publication practices" (mentioned as mandated in 78–79% of organizations (Source: pmc.ncbi.nlm.nih.gov) is aimed at preventing undisclosed writing assistance.

- **Quality and Standardization:** With so many providers and freelance writers globally (including non-native English speakers), maintaining high quality is a focus. Agencies implement rigorous editorial reviews and offer training. Some sponsors approve only writers certified by recognized bodies or with extensive experience in the particular therapy area. Checklists like CONSORT, ICH guidelines, and client style manuals are standard tools. The industry also has begun exploring digital solutions (e.g. publication tracking software) to ensure no submissions fall through cracks.

- **Competitive Pressure:** As the number of players grows (note the 1,148 companies identified (Source: academic.oup.com), competition has driven some price pressure on commoditized tasks (like editing). However, specialized expertise (rare disease, highly technical fields) still commands premium rates. Large CROs with global scale can integrate writing into broader service contracts, complicating price comparisons.

- **Talent Shortage and Training:** Despite expansion, there is an acknowledged shortage of skilled writers. As Mordor comments, the scarcity of experienced writers is causing wages to inflate and pushing adoption of AI tools (Source: www.mordorintelligence.com). Many organizations therefore recruit from regions with lower labor costs, and invest in training. The result is a workforce that is highly diverse globally, but variable in maturity; ensuring consistent quality thus remains a managerial challenge.

- **Regulatory Changes:** New regulatory initiatives (e.g. EMA’s 2014 policy to publish all clinical reports (Source: www.ema.europa.eu), or funders’ open-access mandates) continuously alter the landscape. For example, companies must now plan for open dissemination of trial data (including possibly negative results) that were once optional. Under the EU Clinical Trials Regulation, trial information includes a summary of results and a lay summary. In the United States, NIH policy requires registration and results reporting for NIH-funded clinical trials through ClinicalTrials.gov; it does not establish a general lay-summary requirement. Adapting to these changing norms is an ongoing task for publication planners.

Case Examples and Use-Cases

Although public case studies of companies’ publication plans are rare (due to confidentiality), we can illustrate typical scenarios:

- **Case: New Drug Launch** – A mid-sized pharmaceutical company developed a novel oncology therapy and was preparing for FDA submission. The company engaged a medical communications agency to lead publication planning two years before launch. The plan included references to Phase II results in 2 peer-reviewed journals and multiple abstracts at ASCO and ESMO, timed to precede the NDA submission date. Over two-

year execution, the agency drafted manuscripts, managed KOL authorship rotations, and delivered an internal "publication toolkit" for future investigators. The coordinated strategy ensured that pivotal trial data were in the literature by product approval, maximizing scientific visibility. (This example is representative of industry practice, as described in conference reports (Source: journals.library.ualberta.ca).)

- **Case: Post-Marketing Study Reporting** – A biotech's post-approval safety study, requested by regulators, had negative results. The publication plan called for drafting a manuscript reporting these findings to ensure transparency. Medical writers collaborated with statisticians and physicians to draft the report, carefully framing the conclusions. Despite the unfavorable outcome for the drug, publishing the data in a respected journal upheld scientific integrity. This aligns with guidelines emphasizing publication of all results (including negative) to avoid publication bias.
- **Case: CRO Integration** – A global CRO (e.g. Parexel) offered a full-service package to a client, integrating trial execution with writing. Their team used electronic data from the trial database to auto-populate parts of the Clinical Study Report, and coordinated with writers to draft it concurrently with the study. This illustrates how leading CROs leverage technology (and internal medical writing units) to streamline regulatory document preparation.

These hypothetical examples are grounded in industry descriptions and underscore how publication planning is woven into real project workflows (Source: journals.library.ualberta.ca) (Source: pmc.ncbi.nlm.nih.gov).

Technology and Innovation

The medical writing industry has gradually adopted new technologies to increase productivity and collaboration:

- **Document Management Systems**: Many agencies use platforms (e.g. Veeva Vault, Datavision, or proprietary systems) to manage version control, track review cycles, and host shared lexicons. This ensures consistency across documents and faster access to templates.
- **Reference and Graphics Tools**: Writers commonly rely on advanced referencing software (EndNote, Reference Manager) and graphic/data visualization tools (GraphPad, Adobe Illustrator) to produce high-quality charts and illustrations for manuscripts.
- **AI and Automation**: AI tools have moved beyond pilot programs and are now actively deployed in medical writing workflows. Purpose-built platforms such as **AlphaLife Sciences' AuroraPrime** (used by 5 of the top 10 global pharma companies) can generate "80% complete" regulatory document drafts within minutes, claiming **30–50% reduction in document cycle time** — e.g., CSR timelines reduced from 8–14 weeks to 5–8 weeks (Source: alphalifesci.com). Other platforms include **Trilogy Writing's NEXT** (AI-driven regulatory document drafting), **Deep Intelligent Pharma's** multi-agent platform for end-to-end medical writing automation, and **Yseop Copilot** for NLG-based regulatory document generation. Mordor Intelligence notes that AI adoption is accelerating due to skill shortages (Source: www.mordorintelligence.com). However, regulatory compliance demands human oversight: ISMPP's enhanced AI guidance (September 2025) emphasizes that professionals must complete minimum AI training, ensure proper disclosure, and maintain expert oversight for compliance assurance (Source: tandfonline.com). The **FDA** (January 2025 draft guidance) and a joint **FDA-EMA** statement (January 2026) on AI in drug development have further underscored a human-centric approach to AI use across the entire drug lifecycle (Source: raps.org).
- **Virtual Collaboration**: With COVID-19 accelerating remote work, medical writers now often collaborate across continents via web conferencing, online review platforms, and secure file sharing. Virtual congresses have become common, requiring writers to produce digital slide decks rather than physical posters. These shifts have been largely positive; companies report improved flexibility in deploying global writing teams.
- **Data Analytics**: Some organizations use analytics to measure the impact of publications. For instance, tracking a drug's citation metrics or altmetrics to assess how well a publication plan is performing. In the future, more sophisticated analytics (machine learning over publication data) may further refine planning decisions.

Multiple Perspectives

Pharmaceutical Sponsors: From the sponsor's view, publication planning is critical for product success. It helps establish scientific credibility with the medical community, influences formulary and prescribing decisions, and can mitigate reputational risk by ensuring all data are communicated. Sponsors also must follow ethical and legal requirements (e.g. Sunshine Act in the U.S., GPP codes). In-house teams (medical affairs, marketing) often coordinate publication efforts but rely on external agencies for specialized writing and logistical support.

Medical Communications Agencies: These firms see themselves both as science translators and project managers. They emphasize quality (e.g. employing writers with degrees in pharmacology or medicine) and compliance. At the same time, they operate businesses with competitive pressures. Agencies often highlight success stories (multiplying abstracts to publications, high-impact journals secured) in marketing. They also engage in

knowledge-sharing: for example, agencies like Complete Health Communications co-author articles on best practices in industry publications. Agencies must balance sponsor objectives (market impact) with integrity (accurate science).

Regulators and Journals: Regulatory bodies increasingly demand transparency. For example, the European Medicines Agency's 2015 policy made anonymized patient data and clinical reports publicly available (Source: www.ema.europa.eu). Journals in turn reinforce authorship guidelines to ensure that all contributions (including professional writers) are visible and that claims are credible. Both regulators and journals press companies to publish results, to avoid selective reporting. A recent trend is the requirement that any writing assistance be explicitly disclosed in publications, aligning with the recommendations of GPP 2022 (Source: pubmed.ncbi.nlm.nih.gov). A 2024 BMJ analysis found that 44 of 51 medical journals in its sample with AI guidance prohibited listing generative AI as an author; its sample was drawn from highly ranked scientific journals and does not establish a figure for the "top 100 medical journals" (BMJ bibliometric analysis.

Academic Researchers: Many clinical trialists (often academics) are co-authors on industry-sponsored papers. They benefit from professional writing assistance (which can improve clarity and expedite publication). However, some researchers remain wary of industry influence. The notion that pharmaceutical companies "shape" medical literature (as Sismondo and Nicholson discuss (Source: journals.library.ualberta.ca) is a critique from academics. In response, responsible writers and planners strive for transparency. Some academics even appreciate medical writers: a 2018 editorial argued that declaring medical writer involvement can reduce misconduct (Source: journals.library.ualberta.ca). Nonetheless, the field must continually demonstrate that writers act to enable, not distort, scholarly communication.

Implications and Future Directions

Looking ahead, several trends are poised to influence the field:

- **AI and Automation**: AI-driven writing tools may support productivity, but the scale of any efficiency gain varies by tool, workflow, and the quality of human oversight. Guidance on responsible adoption addresses training, disclosure, and ethical risk assessment (Source: tandfonline.com). AI-generated content requires stringent checks because errors in regulatory documents or scientific publications can have serious consequences. AI is best understood as a tool to support, rather than replace, expert medical writers.
- **Open Science and Transparency**: Moves like Plan S (the initiative for open-access publishing) and increased data sharing will amplify the importance of plain-language communication. Writers will invest more in patient engagement content. Publication planning will have to accommodate new disclosure rules. For example, many agencies now routinely ask whether trial data will be in public databases, to avoid duplicating publication.
- **Patient-Centric Communications**: Regulatory bodies are encouraging lay summaries and other patient-facing materials. Companies recognize that involving patient advocates (as co-authors or reviewers) can improve transparency. Medical writers may increasingly work on patient engagement events or social media content, going beyond professional audiences.
- **Globalization of Talent**: We already see much of the writing work being done in India, China, Eastern Europe, etc., where fluency in English and scientific expertise are high. This trend will continue, with possibly newer centers emerging (e.g. in Latin America or Africa) as they invest in life sciences. This globalization improves availability but requires agencies to manage multicultural teams and ensure consistent client communications.
- **Specialization and Niche Markets**: As the industry matures, we may see more boutique agencies specializing in narrow fields (e.g. rare disease, digital health, immunotherapy publications), competing on content expertise. The top large players will likely continue to consolidate smaller agencies to broaden their service portfolios.

In summary, the combination of strong market growth and evolving technology/standards suggests a robust future for publication planning and medical writing services. These functions will remain critical in bridging scientific discovery and clinical practice, albeit with new tools and stricter transparency norms.

Conclusion

Scientific publication planning and medical writing have become indispensable facets of modern pharmaceutical and biomedical industries. The market for these services is large and still growing (estimates of **$3.8–5.1B** in the mid-2020s, projected to reach **$6–10B+ by 2030–2032**) (Source: www.grandviewresearch.com) (Source: www.mordorintelligence.com). This growth has given rise to a diverse ecosystem of service providers – from huge CROs like IQVIA and Syneos Health (now private) to specialized agencies like Trilogy, Avalere Health, and Indegene – each offering expertise

across regulatory writing, clinical publications, and medical communications. The sector is underpinned by professional guidelines (ICMJE, GPP 2022, code of ethics) which mandate transparency and ethical standards (Source: pubmed.ncbi.nlm.nih.gov) (Source: journals.library.ualberta.ca). Empirical studies document medical-writing support in published research. For example, one cross-sectional sample found that 141 of 270 oncology trials in six high-impact medical and oncology journals identified a medical writer; that disclosure-based sample cannot establish writer use across all such papers (Source: pmc.ncbi.nlm.nih.gov). A separate survey found that responding companies commonly required acknowledgement of writing support (Source: pmc.ncbi.nlm.nih.gov).

Looking forward, technological innovations (digital platforms, AI) and changing norms (open access, patient engagement) are reshaping the field. Stakeholders remain mindful of quality and ethics – the shadow of past practices (ghostwriting) keeps transparency front-and-center. For the foreseeable future, well-trained publication planners and medical writers will be essential to ensure that burgeoning scientific data is communicated accurately, effectively, and in compliance with all standards.

References: This report has drawn on market research (e.g. Grand View Research, Mordor Intelligence) (Source: www.grandviewresearch.com) (Source: www.mordorintelligence.com), peer-reviewed studies (e.g. JAMA *Network Open* on writer use (Source: pmc.ncbi.nlm.nih.gov); BMJ Open survey on guideline awareness (Source: pmc.ncbi.nlm.nih.gov); an authoritative review on industry publishing practices (Source: journals.library.ualberta.ca), regulatory publications (EMA policy) (Source: www.ema.europa.eu), and industry news/agency profiles (Source: www.verifiedmarketresearch.com) (Source: www.verifiedmarketresearch.com). These sources provide context for selected market estimates, surveys, guidance, and industry developments discussed in this report.

Tags: medical writing, publication planning, regulatory writing, gpp guidelines, clinical trial publications, scientific communications, cro services

IntuitionLabs - Industry Leadership & Services

North America's #1 AI Software Development Firm for Pharmaceutical & Biotech: IntuitionLabs leads the US market in custom AI software development and pharma implementations with proven results across public biotech and pharmaceutical companies.

Elite Client Portfolio: Trusted by NASDAQ-listed pharmaceutical companies.

Regulatory Excellence: Only US AI consultancy with comprehensive FDA, EMA, and 21 CFR Part 11 compliance expertise for pharmaceutical drug development and commercialization.

Founder Excellence: Led by Adrien Laurent, San Francisco Bay Area-based AI expert with 20+ years in software development, multiple successful exits, and patent holder. Recognized as one of the top AI experts in the USA.

Custom AI Software Development: Build tailored pharmaceutical AI applications, custom CRMs, chatbots, and ERP systems with advanced analytics and regulatory compliance capabilities.

Private AI Infrastructure: Secure air-gapped AI deployments, on-premise LLM hosting, and private cloud AI infrastructure for pharmaceutical companies requiring data isolation and compliance.

Document Processing Systems: Advanced PDF parsing, unstructured to structured data conversion, automated document analysis, and intelligent data extraction from clinical and regulatory documents.

Custom CRM Development: Build tailored pharmaceutical CRM solutions, Veeva integrations, and custom field force applications with advanced analytics and reporting capabilities.

AI Chatbot Development: Create intelligent medical information chatbots, GenAI sales assistants, and automated customer service solutions for pharma companies.

Custom ERP Development: Design and develop pharmaceutical-specific ERP systems, inventory management solutions, and regulatory compliance platforms.

Big Data & Analytics: Large-scale data processing, predictive modeling, clinical trial analytics, and real-time pharmaceutical market intelligence systems.

Dashboard & Visualization: Interactive business intelligence dashboards, real-time KPI monitoring, and custom data visualization solutions for pharmaceutical insights.

Leading Claude & ChatGPT AI Enablement and Training: Help biotech and pharmaceutical teams adopt Claude and ChatGPT through practical training, governed workflows, use-case development, and implementation designed for regulated environments.

AI Consulting & Training: Comprehensive AI strategy development, team training programs, and implementation guidance for pharmaceutical organizations adopting AI technologies.

Contact founder Adrien Laurent and team at intuitionlabs.ai/contact for a consultation.

DISCLAIMER

The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein.

Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document.

This document may contain content generated with the assistance of artificial intelligence technologies. AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it.

All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders.

IntuitionLabs.ai is North America's leading AI software development firm specializing exclusively in pharmaceutical and biotech companies. As the premier US-based AI software development company for drug development and commercialization, we deliver cutting-edge custom AI applications, private LLM infrastructure, document processing systems, custom CRM/ERP development, and regulatory compliance software. Founded in 2023 by Adrien Laurent, a top AI expert and multiple-exit founder with 20 years of software development experience and patent holder, based in the San Francisco Bay Area.

This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.

© 2026 IntuitionLabs.ai. All rights reserved.